

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION**

**MDL No. 2724
16-MD-2724**

***IN RE: CLOBETASOL CASES
IN RE: CLOMIPRAMINE CASES***

**DPP CASE: 16-CB-27241
DPP CASE: 16-CM-27241**

THIS DOCUMENT RELATES TO:

HON. CYNTHIA M. RUFÉ

***DIRECT PURCHASER PLAINTIFFS’
BELLWETHER ACTIONS***

**NOTICE OF FILING OF OPT-OUT REPORT FOR
DIRECT PURCHASER PLAINTIFFS’ CLOBETASOL AND CLOMIPRAMINE CLASSES**

Pursuant to Paragraph 7 of this Court’s April 23, 2025 Order Approving the Form and Manner of Notice and Appointing Notice Administrator [MDL Doc. No. 3349] and Paragraph 5 of this Court’s June 21, 2025 Order Approving The Bellwether Parties’ Joint Stipulation Related to a Stay of Proceedings Pending Rule 23(f) Appeals [MDL Doc. No. 3478], Direct Purchaser Plaintiffs (“DPPs”) hereby provide notice of filing the attached Declaration of Eric J. Miller Regarding (A) Dissemination of the Notice and (B) Report on Requests for Exclusion and Objections, If Any, Received to Date for DPPs’ *Clobetasol* and *Clomipramine* Classes.

Dated: July 15, 2025

Respectfully submitted,



Dianne M. Nast
NASTLAW LLC
1101 Market Street, Suite 2801
Philadelphia, Pennsylvania 19107
(215) 923-9300
dnast@nastlaw.com

*Lead and Liaison Counsel
for Direct Purchaser Plaintiffs*

David F. Sorensen
BERGER MONTAGUE PC
1818 Market Street, Suite 3600
Philadelphia, Pennsylvania 19103
(215) 875-3000
dsorensen@bm.net

Thomas M. Sobol
HAGENS BERMAN SOBOL SHAPIRO LLP
1 Faneuil Hall Sq., 5th Floor
Boston, Massachusetts 02109
(617) 482-3700
tom@hbsslaw.com

Robert N. Kaplan
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 687-1980
rkaplan@kaplanfox.com

Linda P. Nussbaum
NUSSBAUM LAW GROUP, PC
1133 Avenue of the Americas, 31st Floor
New York, New York 10036
(917) 438-9189
lnussbaum@nussbaumpc.com

Michael L. Roberts
ROBERTS LAW FIRM P.A.
1920 McKinney Ave., Suite 700
Dallas, Texas 75201
(501) 821-5575
mikeroberts@robertslawfirm.us

Direct Purchaser Plaintiffs' Steering Committee

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION**

**MDL No. 2724
16-MD-2724**

***IN RE: CLOBETASOL CASES
IN RE: CLOMIPRAMINE CASES***

**DPP CASE: 16-CB-27241
DPP CASE: 16-CM-27241**

THIS DOCUMENT RELATES TO:

HON. CYNTHIA M. RUFE

***DIRECT PURCHASER PLAINTIFFS’
BELLWETHER ACTIONS***

**DECLARATION OF ERIC J. MILLER REGARDING
(A) DISSEMINATION OF THE NOTICE AND (B) REPORT ON REQUESTS FOR
EXCLUSION AND OBJECTIONS, IF ANY, RECEIVED TO DATE FOR
DPPS’ CLOBETASOL AND CLOMIPRAMINE CLASSES**

I, Eric J. Miller, hereby declare and state as follows:

1. I am a Senior Vice President with A.B. Data, Ltd. (“A.B. Data”). I am fully familiar with the facts contained herein based upon my personal knowledge, and if called to testify as a witness, could and would testify competently thereto. I submit this declaration at the request of Class Counsel in connection with the above-captioned action (the “Action”).

2. A.B. Data was appointed by the Court in its Order Approving the Form and Manner of Notice and Appointing Notice Administrator dated April 23, 2025 to serve as the notice administrator for the Direct Purchaser Plaintiffs’ (“DPPs”) certified *Clobetasol* and *Clomipramine* classes. MDL Doc. No. 3349 (“Notice Order”). A.B. Data’s duties in this case include administering the distribution of a joint notice of these two classes to members of either class. I am submitting this declaration to advise the Court of A.B. Data’s activities concerning distribution of notice and the results.

Direct Mail and Email Notice

3. A.B. Data obtained from Class Counsel a list of 128 *Clobetasol* Class members and a second list of 69 *Clomipramine* Class members both developed by Class Counsel's experts from transactional data produced by the defendants in discovery.

4. These two lists overlapped with some class members common to both classes. Accordingly, because I was tasked with sending out one joint Notice concerning both classes, I cross-checked the class lists and found that there were 136 unique members of either class to which I would send Notice.

5. Class Counsel performed research to locate mailing addresses for these Class members. Where a Class member had multiple locations, each of the addresses was captured and included in the mailing database. In addition, A.B. Data supplemented the list with additional mailing addresses through review of A.B. Data's own records from other direct purchaser pharmaceutical appointments and further independent research.

6. As a result of these efforts, A.B. Data obtained the identity and mailing addresses of 122 of 136 class members across both classes and a total of 275 mailing addresses for them. A.B. Data and Class Counsel were not able to locate a mailing address for 14 Class members because each is either no longer in business or its name incomplete so the actual entity could not be located.

7. On May 2, 2025, A.B. Data arranged for the mailing of the Long Form Notice (the "Notice") to 122 Class members. The Notice was also mailed to the additional addresses for certain Class members. On the same day, A.B. Data posted the Notice on www.GenericDrugDirectClasses.com, the website created for this litigation. In accordance with Paragraph 3 of the Court's Notice Order, A.B. Data also caused email notice to 46 email

addresses associated with 30 of the 136 Class members. A copy of the Notice is attached hereto as **Exhibit A**.

8. In sum, A.B. Data caused 321 Notices to be mailed or emailed to Class members. If all mailings to a Class member were returned as undeliverable as addressed by the United States Postal Service, A.B. Data performed additional research to locate an updated address or determine if the Class member was no longer in existence. When A.B. Data was able to locate an updated address, A.B. Data promptly remailed the Notice to the updated address.

Media Notice

9. To supplement direct notice efforts, beginning on May 2, 2025, A.B. Data caused digital banner ads to appear on The Pink Sheet website for a period of 30 days. The Pink Sheet reaches over 3,000 of the world's leading pharmaceutical, contract research organizations (CROs), medical technology, biotechnology and healthcare service providers, including the top 50 global pharma and top 10 CROs. These ads appeared on both desktop and mobile formats. 99,994 impressions have been delivered through the conclusion of the media notice on June 1, 2025. A sample of the digital banner and newsfeed ads are attached as **Exhibit B**.

10. A.B. Data also caused the Short Form Notice to be published in *The Wall Street Journal* on May 2, 2025. A copy is attached hereto as **Exhibit C**.

News Media

11. On May 2, 2025, A.B. Data disseminated a news release via Business Wire to announce this Court's certification of these classes. This news release distributed via Business Wire went to the news desks of approximately 10,000 newsrooms, including those of print, broadcast, and digital websites across the United States. A copy of the news release is attached as **Exhibit D**.

Website and Telephone

12. To assist Class members in understanding the terms of the notice and their rights, A.B. Data utilized a case-specific toll-free telephone number (877-315-0583), email address (info@GenericDrugDirectClasses.com), and website (www. GenericDrugDirectClasses.com).

13. On May 2, 2024, A.B. Data updated the case-specific toll-free telephone number to include an interactive voice response (“IVR”) system which provided summary information to frequently asked questions specific to the *Clobetasol* and *Clomipramine* classes. This also provided callers the opportunity to speak with a live customer support representative. In addition, A.B. Data has received emails to the email address established for this matter.

14. On May 2, 2025, A.B. Data updated the case-specific website, www.GenericDrugDirectClasses.com to include information about the certified classes. The website address appeared on the Notice and the newswire. The website includes case-specific information, including relevant deadlines and downloadable versions of the Notice, the complaints, the order granting class certification, the Notice Order, and, after its entry on June 21, 2025, this Court’s Order Approving Joint Stipulation Related to Stay of Proceedings Pending Rule 23(f) Appeals. To date, the website has had 814 visitors.

Requests for Exclusion and Objections

15. Pursuant to the Court’s Notice Order, any Class member requesting exclusion from either or both of the *Clobetasol* and *Clomipramine* classes was required to postmark such a request on or before July 1, 2025.

16. As of the date of this Declaration, A.B. Data has received copies of nine (9) letters postmarked on or before July 1, 2025 that request exclusion of certain referenced entities

from both classes. Each letter was sent by counsel who represent certain Direct Action Plaintiffs (“DAPs”) that I understand have brought individual claims in the MDL.

17. These nine timely letters purport to reference, expressly or indirectly, dozens of entities requesting exclusion from both classes and listed in the attached **Exhibit E**. Many of the dozens of entities referenced by these letters and listed in Exhibit E, however, do not appear on the class list for either *Clobetasol* or *Clomipramine*. Two of the nine timely letters appear to relate to entities that do not appear at all on either the *Clobetasol* or *Clomipramine* class list. Through these nine timely letters and as identified in the attached **Exhibit F**, it appears that only eleven (11) members of the *Clobetasol* Class and nine (9) members of the *Clomipramine* Class have submitted timely request for exclusion.

18. On July 11, 2025, A.B. Data received one (1) untimely letter via email from additional DAP counsel requesting exclusion from both classes of certain entities identified in the attached **Exhibit G**. To date, A.B. Data has to date not received a postmarked copy of that letter. On July 15, 2025 A.B. Data learned from Class Counsel that DAP counsel has contacted Class Counsel about the untimely request and confirmed that the letter emailed to A.B. Data on July 11, 2025 was not postmarked on or before July 1, 2025 but rather on July 10, 2025.

19. Many of the dozens of entities referenced by this untimely letter and listed in Exhibit G, however, do not appear on the class list for either *Clobetasol* or *Clomipramine*. Instead, as identified in the attached **Exhibit H**, it appears this untimely letter pertains to only eight (8) members of the *Clobetasol* Class and seven (7) members of the *Clomipramine* Class.

20. Pursuant to the Court’s Preliminary Approval Order, the postmark deadline for a Class member to object to the *Clobetasol* or *Clomipramine* Class was also July 1, 2025.

21. The Notice directs members of the Classes to mail their objection to Clerk of the United States District Court for the Eastern District of Pennsylvania with copies to Class Counsel and Settling Defendants' Counsel.

22. As of the date of this Declaration, A.B. Data has not been notified of any objections.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on July 15, 2025


Eric J. Miller

EXHIBIT A

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

If you purchased the pharmaceutical
Clobetasol directly from Actavis Holdco
U.S. Inc.; Akorn, Inc.; Fougera
Pharmaceuticals Inc.; Hi-Tech Pharmacal
Co. Inc.; Sandoz, Inc.; Morton Grove
Pharmaceuticals, Inc.; Taro
Pharmaceuticals U.S.A. Inc.; or Wockhardt
USA LLC at any time from June 3, 2014 to
December 31, 2018,

Or

If you purchased the pharmaceutical
Clomipramine directly from Mylan Inc.;
Mylan Pharmaceuticals, Inc.; Sandoz, Inc.;
or Taro Pharmaceuticals U.S.A., Inc. at
any time from May 1, 2013 to December 31,
2018, a class action lawsuit could affect
your rights.

A federal court authorized this notice. This is not a solicitation from a lawyer.

- The purpose of this notice is to alert you of Class Action Lawsuits (the “Lawsuits”) brought by Direct Purchasers of Clobetasol and Direct Purchasers of Clomipramine (“Direct Purchaser Plaintiffs” or “DPPs”). The Lawsuits concern two pharmaceuticals and are part of a group of direct purchaser class actions coordinated under the civil docket *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa). There are two lawsuits that are the subject of this notice – one concerns Clobetasol, and one concerns Clomipramine. The Lawsuits each claim that generic drug manufacturers violated antitrust laws, harming competition and causing Class Members to overpay for the products.
- The DPPs bring the Clobetasol Lawsuit against Actavis Holdco U.S. Inc.; Akorn, Inc.; Fougere Pharmaceuticals Inc.; Hi-Tech Pharmacal Co. Inc.; Sandoz, Inc; Morton Grove Pharmaceuticals, Inc.; Taro Pharmaceuticals U.S.A. Inc.; and Wockhardt USA LLC (“Clobetasol Defendants”).
- The DPPs bring the Clomipramine Lawsuit against Mylan Inc.; Mylan Pharmaceuticals, Inc.; Sandoz, Inc.; and Taro Pharmaceuticals U.S.A., Inc. (“Clomipramine Defendants”).
- Some Defendants, Fougere Pharmaceuticals Inc; Sandoz, Inc.; and Taro Pharmaceuticals U.S.A. Inc., have settled the claims against them in the DPPs’ coordinated actions; you have already received notice of those settlements. While they are no longer Defendants in the Lawsuits, the DPPs continue to seek damages for their sales of Clobetasol and/or Clomipramine from the remaining Defendants. All Defendants deny liability as alleged in the Lawsuits and deny that any Class member is entitled to damages or other relief.
- The Court has approved the Lawsuits between Direct Purchaser Plaintiffs and Defendants to proceed as class actions because they meet the requirements of Federal Rule of Civil Procedure 23, which governs class actions in federal courts. The two certified classes (hereinafter the “Direct Purchaser Classes” or the “Classes”) include:

For Clobetasol:

All persons or entities that directly purchased clobetasol (generic clobetasol propionate topical ointment .05% (15, 30, 45, or 60 gm), topical solution .05% (25 or 50 ml), topical gel .05% (15, 30, or 60 gm), topical cream .05% (15, 30, 45, or 60 gm), or topical emollient cream .05% (15, 30, or 60 gm)) from one or more of the Clobetasol Defendants in the United States and its territories and possessions at any time during the period from June 3, 2014 through December 31, 2018 (the “Clobetasol Class Period”). Excluded from the Clobetasol Class are (a) the Defendants and former defendants [] and their officers, directors, management, employees, subsidiaries, or affiliates, (b) judicial officers and their personnel, (c) all governmental entities, and (d) all persons or entities that (i) purchased at least one form of clobetasol (i.e., ointment, topical solution, topical gel, topical cream, or topical emollient cream) during the period May 15, 2013 to May 14, 2014 (“Clobetasol Pre Period”) and at least one of the same forms during the Clobetasol Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the form(s) purchased in both Periods did not increase

during the Clobetasol Class Period as compared to the Clobetasol Pre Period. (“Clobetasol Class”)

For Clomipramine:

All persons or entities that directly purchased clomipramine (generic clomipramine hydrochloride 25, 50, or 75mg capsules) from one or more of the Clomipramine Defendants in the United States and its territories and possessions at any time during the period from May 1, 2013 through December 31, 2018 (the “Clomipramine Class Period”). Excluded from the Clomipramine Class are (a) the Defendants or former defendants [] and their officers, directors, management, employees, subsidiaries, or affiliates, (b) judicial officers and their personnel, (c) all governmental entities, and (d) all persons or entities that (i) purchased at least one strength of clomipramine (i.e., 25, 50, or 75mg capsules) during the period March 18, 2012 to March 17, 2013 (“Clomipramine Pre Period”) and at least one of the same strengths during the Clomipramine Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the strength(s) purchased in both Periods did not increase during the Clomipramine Class Period as compared to the Clomipramine PrePeriod. (“Clomipramine Class”)

- Each class has a unique class definition and involves unique claims and defenses. Defendants and class representatives, with some exceptions, differ between the two classes. Defendants filed petitions for permission to appeal the orders certifying the classes; it is possible that one or both classes may be modified or decertified.
- You may be a member of the Clobetasol Class, the Clomipramine Class, both classes, or neither class.
- There has been no determination by the Court or a jury that DPPs have sufficiently proven their allegations against the Defendants or that, if proven, the conduct caused harm to any Class Members. Defendants have filed motions for summary judgment, that, if granted, may resolve one or both Lawsuits in their favor. Neither the Court nor a jury has decided who is right. There is no money available now and no guarantee there will be. However, your rights are affected and you have a choice to make now.

YOUR LEGAL RIGHTS ARE AFFECTED WHETHER YOU ACT OR DO NOT ACT,
SO PLEASE READ THIS NOTICE CAREFULLY

YOUR LEGAL RIGHTS AND OPTIONS	
DO NOTHING	By doing nothing, you remain in the Direct Purchaser Classes and may be entitled to share in any recovery that may come from a trial or settlement with Defendants. All the Court's orders will apply to you and legally bind you. You will not be able to start another lawsuit, continue another lawsuit, or be part of any other lawsuit against Defendants about the legal and factual issues in the Clobetasol or Clomipramine cases.
EXCLUDE YOURSELF FROM THE CLASSES	You may choose to exclude yourself, or "opt-out," from one or both of the Direct Purchaser Classes. If you choose to exclude yourself, you will not be bound by any decision in the Lawsuit from which you exclude yourself. This is the only option that allows you to ever be part of any lawsuit (other than these Lawsuits) against the Defendants about these legal claims against the Defendants with respect to your purchases of Clobetasol or Clomipramine.
GET MORE INFORMATION	If you would like to obtain more information about the Lawsuits, you can send questions to the lawyers identified in this notice.

*These rights and options – **and the deadlines to exercise them** – are explained in this notice.*

TABLE OF CONTENTS

WHAT THIS NOTICE CONTAINS

BASIC INFORMATION	PAGE 6
1. Why did I get this notice?	PAGE 6
2. What are these lawsuits about?	PAGE 6
3. What is a class action?	PAGE 7
4. Has the Court identified Class claims, issues, or defenses?	PAGE 7
5. What are the DPPs asking for?	PAGE 7
6. Is there additional money available now?	PAGE 7
WHO IS IN THE DIRECT PURCHASER CLASSES	PAGE 8
7. Am I part of the Clobetasol Class and/or the Clomipramine Class?	PAGE 8
EXCLUDING YOURSELF FROM THE DIRECT PURCHASER CLASSES	PAGE 9
8. Can I get out of the Lawsuits?	PAGE 9
9. If I excluded myself from the previous settlements, am I still part of the Direct Purchaser Classes?	PAGE 9
THE LAWYERS REPRESENTING THE CLASSES	PAGE 10
10. Do I have a lawyer in these cases?	PAGE 10
11. Should I get my own lawyer?	PAGE 10
12. How will the lawyers be paid?	PAGE 10
POTENTIAL TRIAL(S)	PAGE 11
13. How and when will the Court decide who is right?	PAGE 11
14. Do I have to come to trial, if any occur?	PAGE 11
IF YOU DO NOTHING	PAGE 11
15. What happens if I do nothing at all?	PAGE 11
GETTING MORE INFORMATION	PAGE 12
16. How do I get more information?	PAGE 12

BASIC INFORMATION

1. WHY DID I GET THIS NOTICE?

You received this notice because, according to available data and documents, you may have purchased Clobetasol and/or Clomipramine directly from one or more generic manufacturer Defendants during one or both of the class periods:

For Clobetasol, from June 3, 2014 through December 31, 2018, from Actavis Holdco U.S. Inc.; Akorn, Inc.; Fougere Pharmaceuticals Inc.; Hi-Tech Pharmacal Co. Inc.; Sandoz, Inc.; Morton Grove Pharmaceuticals, Inc.; Taro Pharmaceuticals U.S.A. Inc.; and/or Wockhardt USA LLC.

For Clomipramine, May 1, 2013 through December 31, 2018, from Mylan Inc.; Mylan Pharmaceuticals, Inc.; Sandoz, Inc.; and/or Taro Pharmaceuticals U.S.A., Inc.

Therefore, you may be a member of one or both of the Direct Purchaser Classes that were certified by the Court as class actions for purposes of the Lawsuits against the Defendants. This means that the Lawsuits meet the requirements for class actions. Defendants filed petitions for permission to appeal the orders certifying the classes; it is possible that one or both classes may be modified or decertified.

If you are included in the Clobetasol Class and/or the Clomipramine Class, you have a right to know your rights and options before the Court rules on the merits or holds a trial. This notice explains these rights and options.

2. WHAT ARE THESE LAWSUITS ABOUT?

A federal court has certified two classes (the “Clobetasol Class” and the “Clomipramine Class”) in two class action lawsuits brought by Direct Purchasers in *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724. DPPs’ class action complaints are available at www.GenericDrugDirectClasses.com. Judge Cynthia M. Rufe, of the United States District Court for the Eastern District of Pennsylvania (the “Court”), is overseeing the Lawsuits.

There are two lawsuits that are the subject of this notice – one concerns Clobetasol, and one concerns Clomipramine. In each, the Direct Purchaser Plaintiffs claim that Defendants engaged in an unlawful scheme or schemes to fix, maintain, and stabilize prices, of generic drugs in violation of federal antitrust laws. DPPs allege that this harmed competition and caused Class Members to overpay for Clobetasol and Clomipramine.

All Defendants, including the settling defendants, deny that any Class Member is entitled to damages or other relief. All Defendants deny liability as alleged in the Lawsuits and deny that any Class member is entitled to damages or other relief.

There has been no determination by the Court or a jury that the allegations against the Defendants have been proven or that, if proven, the conduct caused harm to any Class Members. No trial has been held. Defendants have filed motions for summary judgment, that, if granted, may resolve one or both Lawsuits in their favor.

Neither the Court nor a jury has decided whether DPPs have sufficiently proved that any defendant violated any laws. This notice is not an expression of any opinion by the Court as to

the merits of Direct Purchaser Plaintiffs' claims against any Defendant or the defenses asserted by any Defendant.

3. WHAT IS A CLASS ACTION?

In a class action, one or more people called “Class Representatives” sue on behalf of others who have similar claims.

In this case, the Court appointed César Castillo, LLC; FWK Holdings, LLC; Rochester Drug Co-Operative, Inc.; and KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. as class representatives for the Clobetasol Class. The Court appointed FWK Holdings, LLC; Rochester Drug Co-Operative, Inc.; and KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. as Class Representatives for the Clomipramine Class.

The Class Representatives and the entities on whose behalf they have sued together constitute the “Class” or “Class Members.” They are also called the “Direct Purchaser Plaintiffs.” Their attorneys are called “Plaintiffs’ Counsel,” “Lead Counsel for the Class,” or “Class Counsel.”

In a class action lawsuit, one court resolves the issues for all Class Members, except for those who exclude themselves (i.e., “opt out”) from the Class. The District Court, by opinion and order filed on March 7, 2025, has determined that the Lawsuits by Direct Purchaser Plaintiffs against the Defendants can proceed as class actions. Copies of the Court’s order and opinion may be found at www.GenericDrugDirectClasses.com.

Defendants filed petitions for permission to appeal the orders certifying the classes; it is possible that one or both classes may be modified or decertified.

4. HAS THE COURT IDENTIFIED CLASS CLAIMS, ISSUES, OR DEFENSES?

The Court has ordered that all Clobetasol and Clomipramine claims and defenses shall proceed as class actions. DPPs allege Defendants violated Section 1 of the Sherman Antitrust Act. Section 1 prohibits agreements between competitors that unreasonably restrain interstate commerce.

5. WHAT ARE THE DPPs ASKING FOR?

Plaintiffs are asking for money for the Direct Purchaser Classes from the remaining Defendants who have not settled.

6. IS THERE ADDITIONAL MONEY AVAILABLE NOW?

No. Previously, some Defendants settled the claims against them in the DPPs’ coordinated actions. You received notice of those settlements.

However, no additional money is available now because the Court and/or jury has not yet decided whether the remaining Defendants did anything wrong, and the DPPs and the remaining Defendants have not settled the case. There is no guarantee that money or benefits will ever be obtained. If they are, you will be notified.

WHO IS IN THE DIRECT PURCHASER CLASSES

7. AM I PART OF THE CLOBETASOL CLASS AND/OR THE CLOMIPRAMINE CLASS?

You are part of the Clobetasol Class if you are a person or entity in the United States and its territories that purchased Clobetasol from one or more Current or Former Defendants (Actavis Holdco U.S.A. Inc.; Akorn, Inc.; Fougera Pharmaceuticals Inc.; Hi-Tech Pharmacal Co. Inc.; Sandoz, Inc.; Morton Grove Pharmaceuticals, Inc.; Taro Pharmaceuticals U.S.A. Inc.; and Wockhardt USA LLC) at any time from June 3, 2014 through December 31, 2018.

Excluded from the Clobetasol Class are:

Current or Former Defendants and their officers, directors, management, employees, subsidiaries, or affiliates; judicial officers and their personnel; all government entities; and,

All persons or entities that (i) purchased at least one form of clobetasol (i.e., ointment, topical solution, topical gel, topical cream, or topical emollient cream) during the period May 15, 2013 to May 14, 2014 (“Clobetasol Pre Period”) and at least one of the same forms during the Clobetasol Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the form(s) purchased in both Periods did not increase during the Clobetasol Class Period as compared to the Clobetasol Pre Period.

You are part of the Clomipramine Class if you are a person or entity in the United States and its territories that purchased Clomipramine from one or more Current or Former Defendants (Mylan Inc.; Mylan Pharmaceuticals, Inc.; Sandoz, Inc.; and Taro Pharmaceuticals U.S.A., Inc.) at any time from and/or May 1, 2013 through December 31, 2018.

Excluded from the Clomipramine Class are:

Current or Former Defendants and their officers, directors, management, employees, subsidiaries, or affiliates; judicial officers and their personnel; all government entities; and,

All persons or entities that (i) purchased at least one strength of clomipramine (i.e., 25, 50, or 75mg capsules) during the period March 18, 2012 to March 17, 2013 (“Clomipramine Pre Period”) and at least one of the same strengths during the Clomipramine Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the strength(s) purchased in both Periods did not increase during the Clomipramine Class Period as compared to the Clomipramine PrePeriod.

You may be a member of the Clobetasol Class, the Clomipramine Class, both classes, or neither class. A list of National Drug Codes (“NDCs”) for Clobetasol and Clomipramine are available at www.GenericDrugDirectClasses.com.

If you are not sure whether you are included in the Clobetasol Class and/or the Clomipramine Class, you may call or write to the lawyers in this case at the telephone numbers or addresses listed in Question 10 below. If you wish to exclude yourself from one or more of these Classes, please see Question 8.

EXCLUDING YOURSELF FROM THE DIRECT PURCHASER CLASSES

8. CAN I GET OUT OF THE LAWSUITS?

Yes, if you exclude yourself from the Clobetasol Class, the Clomipramine Class, or both of the Direct Purchaser Classes, or “opt out,” on or before July 1, 2025, 60 days from the date this notice is mailed (May 2, 2025).

If you are a member of both classes, you may exclude yourself from one class, both classes, or neither class.

To exclude yourself, you must send a letter via first class U.S. mail *or* by email (though we recommend you do both) saying you want to exclude yourself from one or both Direct Purchaser Class Actions in *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa.). Please specify if you wish to exclude yourself from the Clobetasol Class Action, the Clomipramine Class Action, or both the Clobetasol Class and the Clomipramine Class. Be sure to include your name, address, email address, telephone number, and your signature.

Your letter or email requesting exclusion must be postmarked/sent no later than July 1, 2025.

Mail the letter to: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217.

Send email to: info@GenericDrugDirectClasses.com.

If your right to recover stems from your own qualifying purchases of Clobetasol or Clomipramine, no more is required of you.

If you exclude yourself from one or both classes, you will not be legally bound by anything that happens in the Lawsuits between DPPs and the Defendants concerning Clobetasol and/or Clomipramine. This means that you may be able to sue (or continue to sue) the Defendants in the future about the legal issues in these cases involving Clobetasol and/or Clomipramine. If you exclude yourself from the Class(es) so that you can start or continue your own lawsuit against one or more of the Defendants, you should talk to your own lawyer immediately because your claims will be subject to a statute of limitations, which means that your claims will expire if you do not take timely action. **You need to contact your own lawyer about this issue.**

If you do not exclude yourself from the class(es), you will keep the right to a share of any recovery that may come from a trial or settlement of the Lawsuit(s) against Defendants. You will not be able to start another lawsuit, continue another lawsuit, or be part of any other lawsuit against Defendants about the legal issues involving Clobetasol and/or Clomipramine in these Lawsuits regardless of whether there is a recovery. All the Court’s orders in the case(s) by the Direct Purchaser Plaintiffs against Defendants will apply to you and legally bind you. You will also be bound by any judgment in the Lawsuit(s).

9. IF I EXCLUDED MYSELF FROM THE PREVIOUS SETTLEMENTS, AM I STILL PART OF THE DIRECT PURCHASER CLASSES?

Yes. If you are a member of the Clobetasol Class, the Clomipramine Class, or both Direct Purchaser Classes, even if you excluded yourself from the previous settlements, you will still be part of the Direct Purchaser Classes in these Lawsuits unless you exclude yourself now (see Question 8).

THE LAWYERS REPRESENTING THE CLASSES

10. DO I HAVE A LAWYER IN THESE CASES?

The Court appointed the counsel listed below as Class Counsel:

Dianne M. Nast, Esq. Joseph N. Roda, Esq. NASTLAW LLC 1101 Market Street, Suite 2801 Philadelphia, Pennsylvania 19107 215-923-9300 dnast@nastlaw.com jnroda@nastlaw.com	David F. Sorensen, Esq. BERGER MONTAGUE PC 1818 Market Street, Suite 3600 Philadelphia, PA 19103 (215) 875-3000 dsorensen@bm.net
Robert N. Kaplan KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue New York, New York 10022 (212) 687-1980 rkaplan@kaplanfox.com	Thomas M. Sobol, Esq. HAGENS BERMAN SOBOL SHAPIRO LLP 1 Faneuil Hall Square, 5th Floor Boston, Massachusetts 02109 (617) 482-3700 tom@hbsslaw.com
Linda P. Nussbaum NUSSBAUM LAW GROUP, PC 1133 Avenue of the Americas, 31st Floor New York, New York 10036 (917) 438-9189 lnussbaum@nussbaumpc.com	Michael L. Roberts ROBERTS LAW FIRM P.A. 1920 McKinney Ave., Suite 700 Dallas, Texas 75201 (501) 821-5575 mikeroberts@robertslawfirm.us

11. SHOULD I GET MY OWN LAWYER?

The Court has appointed the attorneys above to represent the classes as “Class Counsel.” You don’t have to pay Class Counsel or anyone else to participate or to opt out. You may hire your own lawyer to appear in Court for you, but if you do, you may retain that lawyer at your own expense.

12. HOW WILL THE LAWYERS BE PAID?

If Class Counsel achieves a recovery for a Class, for example by way of settlement or after winning at trial, the Court will be asked to approve reasonable attorneys’ fees, as well as reimbursement of expenses Class Counsel have advanced on behalf of that Class. If the Court grants Class Counsel’s requests, fees and expenses would either be deducted from any money obtained for that Class, or the Court may order the Defendants to pay attorneys’ fees and costs in addition to any damage award to that Class. Members of that Class will not have to pay any attorneys’ fees or expenses except out of money obtained for that Class.

POTENTIAL TRIAL(S)

13. HOW AND WHEN WILL THE COURT DECIDE WHO IS RIGHT?

Defendants have filed motions for summary judgment, that, if granted, may resolve one or both matters in their favor. If the claims against Defendants are not resolved by motion, settlement, or otherwise, Class Counsel will have to prove DPPs' claims at trial. A jury trial is scheduled for August 4, 2025, but the Court has not yet determined whether the trial will include DPPs' claims or relate to Clobetasol or Clomipramine. Each product will be the subject of a separate trial, if any trials occur. There is no guarantee that Direct Purchaser Plaintiffs will win either trial, or that they will get any money for the Direct Purchaser Classes. The trials, if any, will take place at the United States District Court for the Eastern District of Pennsylvania, James A. Byrne U.S. Courthouse, 601 Market Street, Philadelphia, PA 19106 before the Honorable Cynthia M. Rufe. There is no guarantee that DPPs will win, or that they will get any money for the Direct Purchaser Classes. Any judgment will be binding on all members of the Direct Purchaser Classes who have not opted out, regardless of who wins.

14. DO I HAVE TO COME TO THE TRIALS, IF ANY OCCUR?

You do not need to attend the trials, if any occur. Class Counsel will present the case for Direct Purchaser Class Plaintiffs and the Direct Purchaser Classes, and counsel for Defendants will present Defendants' defenses. You and/or your own lawyer are welcome to attend the trials, if any occur, at your own expense. If Direct Purchaser Plaintiffs obtain money as a result of a trial or settlement, you will be notified about how to participate. We do not know how long this will take. Important information about the cases will be posted on the website www.GenericDrugDirectClasses.com as it becomes available.

IF YOU DO NOTHING

15. WHAT HAPPENS IF I DO NOTHING AT ALL?

If you do nothing, you will keep the right to a share of any recovery that may come from a trial or settlement of these Lawsuits against Defendants. There may be no recovery at all. You will not be able to start another lawsuit, continue another lawsuit, or be part of any other lawsuit against Defendants about the legal and factual issues in these cases. All the Court's orders in the case(s) by the DPPs against Defendants will apply to you and legally bind you. You will also be bound by any judgment in the Lawsuit(s).

GETTING MORE INFORMATION

16. HOW DO I GET MORE INFORMATION?

If you have questions about these cases or want additional information, you may call or write to the lawyers listed in answer to Question 10 above, call 877-315-0583, or visit www.GenericDrugDirectClasses.com. You may also view selected filings from the litigation on the Court's PACER system or inspect the papers on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106. Selected filings are available at: www.GenericDrugDirectClasses.com.

PLEASE DO NOT TELEPHONE THE COURT OR THE COURT CLERK'S OFFICE FOR INFORMATION.

DATE: May 2, 2025

BY THE COURT

Honorable Cynthia M. Rufe
United States District Judge
Eastern District of Pennsylvania

EXHIBIT B

Did you purchase
CLOBETASOL and/or
CLOMIPRAMINE directly
from generic drug
manufacturers?

A class action could
affect your rights.

LEARN MORE

GenericDrugDirectClasses.com



**Did you purchase
CLOBETASOL
and/or
CLOMIPRAMINE
directly from
generic drug
manufacturers?**

**A class action could
affect your rights.**



LEARN MORE

GenericDrugDirectClasses.com



**Did you purchase CLOBETASOL and/or CLOMIPRAMINE directly
from generic drug manufacturers?**

A class action could affect your rights.

LEARN MORE

GenericDrugDirectClasses.com

EXHIBIT C

BIGGEST 1,000 STOCKS

How to Read the Stock Tables

The following explanations apply to NYSE, NYSE Arca, NYSE American and Nasdaq Stock Market listed securities. Prices are consolidated from trades reported by various market centers, including securities exchanges, Fint, electronic communications networks and other broker-dealers. The list comprises the 1,000 largest companies based on market capitalization.

Underlined quotations are those stocks with large changes in volume compared with the issue's average trading volume.

Boldfaced quotations highlight those issues whose price changed by 5% or more if their previous closing price was \$2 or higher.

Footnotes:
-N=52-week high; -T=New 52-week low; **dd**=Indicates loss in the most recent four quarters.

Stock tables reflect composite regular trading as of 4 p.m. ET and changes in the official closing prices from 4 p.m. ET the previous day.

Thursday, May 1, 2025																				
Stock	Sym	Close	Net Chg	Stock	Sym	Close	Net Chg	Stock	Sym	Close	Net Chg	Stock	Sym	Close	Net Chg	Stock	Sym	Close	Net Chg	
A B C																				
AAON	AAON	66.46	5.19	ApplMaterials	AMAT	148.96	-1.75	BrookfieldAsset	BAM	53.24	-0.09	CoStar	CSGP	76.58	2.41	DellTechC	DELL	91.95	0.19	
AECOM	ACM	100.25	1.61	ApplProvn	APP	279.49	10.18	Brookfield	BN	54.08	0.41	Costco	COST	999.04	4.54	DellAir	DAL	41.50	-0.13	
Aflac	AFK	103.52	-0.16	ApptgGroup	ATR	148.28	-1.22	BrookfieldInfr	BIP	30.11	0.10	Cognizant	CTSH	24.89	0.33	DescartesSystems	DSGX	104.90	-0.49	
AGNC Invt	AGNC	8.81	-0.02	Aramark	ARMK	33.09	0.04	BrookWealth	BNT	54.05	0.39	Coupage	CPNG	23.47	0.10	DeutscheBank	DB	26.40	0.19	
ASE Tech	ASX	8.70	-0.03	ArcelorMittal	MT	29.70	0.01	Brown&Brown	BFB	34.16	-0.68	DevonEnergy	DVN	31.16	0.71	DiamondBkEnr	FANG	134.83	2.82	
ASML	ASML	666.72	-1.36	AristaCapital	ACGL	98.67	-1.01	BrownForman	BFA	34.32	-0.29	Diageo	DEO	111.31	0.71	EMCOR	EME	412.52	11.82	
AST Space	ASTS	23.02	-0.19	AresMgmt	ARES	152.27	-0.26	BuildersFirst	BLDR	111.92	-7.70	DigitalRealty	DLR	161.88	1.34	DofusSign	DOCU	78.16	-0.61	
ASTS	T	27.64	-0.06	argenx	ARGX	639.90	-5.24	BungeGlobal	BG	78.48	-0.24	DofusSign	DOCU	78.16	-0.61	DofusSign	DOCU	78.16	-0.61	
ATI	ATI	62.24	7.86	AristaNetworks	ANET	87.84	5.57	BurlingtonStrs	BURL	228.00	2.96	DriftdySlab	DRDY	33.26	-0.09	Enbridge	ENB	46.48	-0.21	
AXIS Capital	AXIS	97.42	1.10	Arm	ARM	115.40	1.55	CACI Intl	CACI	458.87	2.10	DofusSign	DOCU	78.16	-0.61	Entegris	ENT	79.30	0.18	
AbbottLabs	ABT	130.88	0.13	AscendisPharma	ASND	167.47	-2.97	CAVA	CAVA	94.53	1.00	EnterpriseProd	EPD	29.87	0.03	Equifax	EFX	351.13	-7.49	
Abbvie	ABBV	193.34	-1.76	Assurant	AIZ	191.63	-1.11	CBRE Group	CBRE	123.52	1.34	Equinix	EQIX	861.97	1.22	Evercore	EVR	206.13	0.84	
Accenture	ACN	300.53	1.38	AsterAals	ALAB	69.22	3.91	CDW	CDW	162.40	1.84	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
Acuity	ACU	241.86	-1.75	AstraZeneca	AZN	70.51	-1.28	CGI A	GIB	104.37	-1.31	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
Adaptive	ADP	298.69	-0.91	Atlasian	TEAM	229.07	0.76	CH Robinson	CHRW	90.28	1.11	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
Adobe	ADBE	374.63	-0.35	AtmosEnergy	AOT	160.18	-0.45	CME Group	CME	277.11	0.03	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AdvDrainageSys	ADMS	113.61	0.12	Auroralnnoy	AUR	68.88	-0.36	CMS Energy	CMS	72.97	-0.68	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AdvMicroDevs	AMD	96.65	-0.70	Autodesk	ADSK	273.49	-0.76	CNA Fin	CNA	47.44	-0.72	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
Aegon	AEG	6.44	0.01	ADP	ADP	298.69	-0.91	CNA Indl	CNI	10.81	0.84	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AerCap	AER	105.89	-0.11	AutoZone	AZO	337.92	-29.68	CNR	CNR	96.28	0.86	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
Affirm	AFFR	49.75	-0.01	Avalonbay	AVB	209.00	-0.98	CSX	CSX	28.11	0.04	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AgilentTechs	A	106.46	-1.14	Avantor	AVTR	12.96	-0.03	CVS Health	CVS	69.45	2.74	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AgilentTechn	AGI	22.01	0.03	AveryDennison	AVY	169.41	-1.70	CadenceDesign	CDNS	299.73	1.99	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
Alcon	ALC	96.17	-1.44	AxonEnterprise	AXON	62.10	7.80	CAE	CAE	25.10	0.08	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlexandriaREITs	ARE	73.42	0.76	BCE	BCE	21.41	0.80	CamdenProperty	CPT	114.83	1.03	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
Alibaba	BABA	120.53	1.10	BHP Group	BHP	47.71	0.16	Camco	CC	45.51	0.36	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AllyBank	ALLY	138.69	-0.51	BJSWholesale	BJ	117.26	-0.30	Campbell's	CPB	35.89	-0.57	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BP	BP	27.88	0.42	CIBC	CIB	63.07	0.12	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BWX Tech	BWXT	111.12	2.00	CINLRIway	CNI	95.62	-1.20	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BXP	BXP	64.28	0.55	CanadianNatRscs	CNQ	28.92	0.23	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	Baidu	BIDU	87.91	0.09	CdnPackC	CP	72.73	0.26	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BakerHughes	BKR	36.19	0.79	Cof	COF	180.22	-0.04	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	Ball	BALL	51.22	-0.77	CardinalHealth	CAH	145.53	4.24	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	Carlisle	CSL	37.79	0.31	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	Carlyle	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.16	0.52	Evercore	EVR	206.13	0.84	Equinix	EQIX	861.97	1.22	
AlliantEnergy	LNT	60.55	-0.49	BBVA	BBVA	11.77	0.07	CarMax	CMX	39.										

EXHIBIT D

May 2, 2025 3:00 PM Eastern Daylight Time

NastLaw LLC

NastLaw LLC Announces a Class Action Lawsuit For Those Who May Have Purchased Clobetasol at Anytime From June 3, 2014 to December 31, 2018 OR Purchased Clomipramine at Anytime From May 1, 2013 to December 31, 2018

RELEASE VERSIONS

English

CONTACTS

Dianne M. Nast, Esq.
Joseph N. Roda, Esq.
(215) 923-9300

Share      ...

PHILADELPHIA--(BUSINESS WIRE)--NastLaw LLC:

Legal Notice

If you purchased the pharmaceutical Clobetasol directly from Actavis Holdco U.S. Inc.; Akorn, Inc.; Fougera Pharmaceuticals Inc.; Hi-Tech Pharmacal Co. Inc.; Sandoz, Inc.; Morton Grove Pharmaceuticals, Inc.; Taro Pharmaceuticals U.S.A., Inc.; or Wockhardt USA LLC at any time from June 3, 2014 to December 31, 2018,

Or

**If you purchased the pharmaceutical Clomipramine directly from Mylan Inc.; Mylan Pharmaceuticals, Inc.; Sandoz, Inc.; or Taro Pharmaceuticals U.S.A., Inc. at any time from May 1, 2013 to December 31, 2018,
a class action lawsuit could affect your rights.**

A federal court authorized this notice. This is not a solicitation from a lawyer.

What are the Lawsuits about? A federal court has certified two classes (the “Clobetasol Class” and the “Clomipramine Class”) in two class action lawsuits brought by Direct Purchasers in *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724. There are two lawsuits that are subject of this notice – one concerns Clobetasol, and one concerns Clomipramine. The lawsuits claim that generic drug manufacturers violated federal antitrust laws, harming competition and causing Class Members to overpay for the products. The Court selected the Clobetasol and Clomipramine lawsuits for bellwether trial(s).

The Clobetasol lawsuit is against Akorn, Inc.; Fougera Pharmaceuticals Inc.; Hi-Tech Pharmacal Co. Inc.; Sandoz, Inc.; Morton Grove Pharmaceuticals, Inc.; Taro Pharmaceuticals U.S.A., Inc.; and Wockhardt USA LLC (“Clobetasol Defendants”).

The Clomipramine Lawsuit is against Mylan Inc.; Mylan Pharmaceuticals, Inc.; Sandoz, Inc.; and Taro Pharmaceuticals U.S.A., Inc. (“Clomipramine Defendants”).

Some Defendants, Fougera Pharmaceuticals Inc; Sandoz, Inc.; and Taro Pharmaceuticals U.S.A. Inc., have settled the claims against them. While they are no longer Defendants in the Lawsuits, the Direct Purchaser Plaintiffs continue to seek damages for their sales of Clobetasol and/or Clomipramine from the remaining Defendants. All Defendants deny liability as alleged in the Lawsuits and deny that any Class member is entitled to damages or other relief.

Each class has a unique class definition and involves unique claims and defenses. Defendants and class representatives, with some exceptions, differ between the two classes. Defendants filed petitions for permission to appeal the orders certifying the classes; it is possible that one or both classes may be modified or decertified.

There has been no determination by the Court or a jury that DPPs have sufficiently proven their allegations against the Defendants or that, if proven, the conduct caused harm to any Class Members. No trial has been held. All Defendants deny liability. Defendants have filed motions for summary judgment, that, if granted, may resolve one or both lawsuits in their favor. Neither the Court nor a jury has decided who is right.

Who is included? The Court certified a Clobetasol Class that includes: All persons or entities that directly purchased clobetasol (generic clobetasol propionate topical ointment .05% (15, 30, 45, or 60 gm), topical solution .05% (25 or 50 ml), topical gel .05% (15, 30, or 60 gm), topical cream .05% (15, 30, 45, or 60 gm), or topical emollient cream .05% (15, 30, or 60 gm)) from one or more of the Clobetasol Defendants in the United States and its territories and possessions at any time during the period from June 3, 2014 through December 31, 2018 (the “Clobetasol Class Period”). Excluded from the Clobetasol Class are (a) the Defendants and former defendants [] and their officers, directors, management, employees, subsidiaries, or affiliates, (b) judicial officers and their personnel, (c) all governmental entities, and (d) all persons or entities that (i) purchased at least one form of clobetasol (i.e., ointment, topical solution, topical gel, topical cream, or topical emollient cream) during the period May 15, 2013 to May 14, 2014 (“Clobetasol Pre Period”) and at least one of the same forms during the Clobetasol Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the form(s) purchased in both Periods did not increase during the Clobetasol Class Period as compared to the Clobetasol Pre Period.

The Court certified a Clomipramine Class that includes: All persons or entities that directly purchased clomipramine (generic clomipramine hydrochloride 25, 50, or 75 mg capsules) from one or more of the Clomipramine Defendants in the United States and its territories and possessions at any time during the period from May 1, 2013 through December 31, 2018 (the “Clomipramine Class Period”). Excluded from the Clomipramine Class are (a) the Defendants or former defendants [] and their officers, directors, management, employees, subsidiaries, or affiliates, (b) judicial officers and their personnel, (c) all governmental entities, and (d) all persons or entities that (i) purchased at least one strength of clomipramine (i.e., 25, 50, or 75 mg capsules)

during the period March 18, 2012 to March 17, 2013 (“Clomipramine Pre Period”) and at least one of the same strengths during the Clomipramine Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the strength(s) purchased in both Periods did not increase during the Clomipramine Class Period as compared to the Clomipramine Pre Period.

The Court’s Opinion and Order certifying these Classes are available at this website: GenericDrugDirectClasses.com. Defendants filed petitions for permission to appeal the orders certifying the classes; it is possible that one or both classes may be modified or decertified.

Who represents the classes? The Court has appointed a group of attorneys from the law firms of NastLaw LLC; Berger Montague PC; Kaplan Fox & Kilsheimer LLP; Hagens Berman Sobol Shapiro LLP; Nussbaum Law Group, PC; and Roberts Law Firm P.A., to represent the classes as “Class Counsel.” You don’t have to pay Class Counsel or anyone else to participate or to opt out. Instead, if Class Counsel gets money or benefits for the classes, they will ask the Court for attorneys’ fees and costs. If approved, these fees and costs would be deducted from any money obtained or paid separately by the Defendants. You may hire your own lawyer to appear in Court for you, but if you do, you may retain that lawyer at your own expense.

How and when will the Court decide who is right? If the claims against the remaining Defendants are not resolved by motion practice, settlement, or otherwise, Class Counsel will have to prove Direct Purchaser Plaintiffs’ claims at trial. A jury trial is scheduled for August 4, 2025, but the Court has not yet determined whether the trial will include DPPs’ claims or relate to Clobetasol or Clomipramine. Each product will be the subject of separate trials, if any trials occur. There is no guarantee that Direct Purchaser Plaintiffs will win either trial, or that they will get any money for the Direct Purchaser Classes. Any judgment will be binding on all members of the Clomipramine and Clobetasol Classes who have not opted out, regardless of who wins.

What are your options? If you are a member of the Clomipramine Class and/or the Clobetasol Class and you do nothing, you will remain in those Class(es).

If you *did not* receive a Notice in the mail, and you think you are a potential Class Member, please identify yourself or your company by mailing a letter to the following address: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217. You may also send an email to info@GenericDrugDirectClasses.com, or call 877-315-0583. You may be required to submit proof of a qualifying direct purchase to establish that you are a Class Member.

As a Class Member, unless you opt out of the Class(es), you will be bound by all orders and judgments of the Court as to the claims relating to Clomipramine and/or Clobetasol in these lawsuits. If money or benefits are obtained, you will be notified.

If you are a member of the Clomipramine Class and/or the Clobetasol Class, and you want to keep your rights to sue the remaining Defendants on your own about the claims in the lawsuits, you must request exclusion from (or opt out of) one or both of the Classes. You must mail your request to opt out by July 1, 2025, to the following address: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217. You may also send an email to info@GenericDrugDirectClasses.com. If you already submitted a request to exclude yourself from the previous settlement classes and do not want to stay in the Clomipramine Class and/or the Clobetasol Class, you still need to exclude yourself now. You can find out how to exclude yourself at the website GenericDrugDirectClasses.com or by calling 877-315-0583.

If you are a member of both the Clobetasol Class and the Clomipramine Class, you may exclude yourself from one class, both classes, or neither class.

For more information: Go to the website GenericDrugDirectClasses.com or call 877-315-0583 for more information on the Classes, the Lawsuits, and your potential rights and options. The website includes, for example, a list of the National Drug Codes (“NDCs”) for Clobetasol and Clomipramine.

Contacts

Dianne M. Nast, Esq.
Joseph N. Roda, Esq.
(215) 923-9300

Industry: [Class Action Lawsuit](#) [Professional Services](#) [Legal](#)

More News From NastLaw LLC

 [Get RSS Feed](#)

Direct Purchaser Plaintiffs Announce Settlements in In Re Generic Pharmaceutical Pricing Antitrust Litigation.

PHILADELPHIA--([BUSINESS WIRE](#))--What is the lawsuit about? Two proposed settlements (the “Settlements”) have been reached in a class action lawsuit (“the Lawsuit”), which alleges that Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual...

[Back to Newsroom](#) →

Wish your news had this kind of reach?

[Sign Up](#) → [Learn About Business Wire](#) →

Company

[About Business Wire](#)
[Careers](#)
[Media Center](#)

Services

[News Release Distribution](#)
[News Release Optimization](#)
[Investor Communications](#)
[Reporting & Analytics](#)

Solutions

[PR Professionals](#)
[IR Professionals](#)
[Agencies](#)
[Public Companies](#)
[Explore by Industry](#)

Newsroom

[Industries](#)
[Subjects](#)
[Languages](#)

Resources

[Blog](#)
[For Journalists](#)
[Sign Up](#)



EXHIBIT E

<u>Entities from Timely Letters Requesting Exclusion</u>	
1	Accredo Health Group, Inc.
2	Albany Area Primary Health Care Inc. Allina Health System
3	Armstrong County Memorial Hospital, d/b/a ACMH Hospital, including from purchases via H.C. Pharmacy Central, Inc. to ACMH Hospital
4	Astera Health, f/k/a Tri-County Health Care Augusta Health Care, Inc., d/b/a/ Augusta Health
5	Avera Health, including Avera McKennan Hospital, Avera St. Luke's Hospital, Avera Sacred Heart Hospital, Avera Queen of Peace Hospital, Avera Heart Hospital of SD, Avera St. Mary's Hospital, Avera Marshall Regional Medical Center, Avera St. Anthony's Hospital, Avera Gregory Healthcare Center, Avera Holy Family, Avera St Benedict Health Center, Milbank Area Hospital Avera, Avera Dells Area Health Center, Avera Creighton Hospital, Avera Hand County Memorial Hospital, Avera Weskota Memorial Medical Center, Avera Missouri River Health Center, Avera De Smet Memorial Hospital, Avera Merrill Pioneer Hospital, Avera Flandreau Medical Center, Avera Granite Falls Hospital, and Avera Tyler Hospital
6	Baptist Health
7	Baxter County Hospital, Inc., d/b/a Baxter Regional Medical Center
8	Baystate Health, Inc., including Baystate Medical Center, Inc., Baystate Franklin Medical Center, Baystate Wing Hospital Corporation, Baystate Noble Hospital Corporation, Baystate Medical Practices, Inc., and Visiting Nurse Association and Hospice of Western New England, Inc.
9	Beaufort Jasper Hampton Comprehensive Health Services, Inc.
10	Berkshire Health Systems, Inc., including Berkshire Medical Center, Inc., Fairview Hospital, Berkshire Apothecary, Inc., and Berkshire Faculty Services, Inc.
11	Billings Clinic, including Daniels Memorial Hospital, Powell Valley Health Care, Inc., Big Horn Hospital Association, Central Montana Medical Facilities, Inc., d/b/a Central Montana Medical Center, Glendive Medical Center, Inc., Livingston HealthCare, Memorial Hospital Association, d/b/a Beartooth Billings Clinic, Pioneer Medical Center, Roundup Memorial Hospital Association, d/b/a Roundup Memorial Healthcare, Sheridan Memorial Hospital Association, South Big Horn County Hospital District, d/b/a Three Rivers Health, Stillwater Hospital Association, Inc., d/b/a Stillwater Billings Clinic, Townsend Health Systems, Inc., d/b/a Billings Clinic Broadwater, Wheatland Memorial Healthcare
12	Bi-Lo
13	Bi-Lo Holding LLC
14	Bi-Lo Holdings, LLC
15	Bi-Lo LLC
16	Bi-Lo, LLC
17	Bravo Health Mid-Atlantic Inc.
18	Bravo Health Pennsylvania Inc.
19	Broad Top Area Medical Centers, Inc.
20	Bruno's Supermarket Incorporated

<u>Entities from Timely Letters Requesting Exclusion</u>	
21	Cape Cod Healthcare, Inc.
22	Care New England Health System, d/b/a Care New England CaroMont Health, Inc.
23	Catamaran
24	CentraCare Health System, including: CentraCare Health - Benson, LLC and Swift County- Benson Health Services
25	Central Texas Community Health Centers d/b/a CommUnityCare Collier Health Services, Inc., d/b/a Healthcare Network Community Health Center of Snohomish
26	Cigna Corporation
27	Cigna Health and Life Insurance Company
28	Cigna HealthCare of Arizona, Inc.
29	Cigna HealthCare of California, Inc.
30	Cigna HealthCare of Colorado, Inc.
31	Cigna HealthCare of Connecticut, Inc.
32	Cigna HealthCare of Florida, Inc.
33	Cigna HealthCare of Georgia, Inc.
34	Cigna HealthCare of Illinois, Inc.
35	Cigna HealthCare of Indiana, Inc.
36	Cigna HealthCare of Maine, Inc.
37	Cigna HealthCare of Massachusetts, Inc.
38	Cigna HealthCare of Mid-Atlantic, Inc.
39	Cigna HealthCare of New Hampshire, Inc.
40	Cigna HealthCare of New Jersey, Inc.
41	Cigna HealthCare of North Carolina, Inc.
42	Cigna HealthCare of Pennsylvania, Inc.
43	Cigna HealthCare of South Carolina, Inc.
44	Cigna HealthCare of St. Louis, Inc.
45	Cigna HealthCare of Tennessee, Inc.
46	Cigna HealthCare of Texas, Inc.
47	Cigna HealthCare of Utah, Inc.
48	Conway Regional Health System
49	Cook County Hospital District, d/b/a North Shore Health Cook Hospital
50	Crusaders Central Clinic Association, including Crusaders Central Clinic Association, d/b/a Crusaders Central Clinic
51	CuraScript, Inc.
52	CVS Caremark
53	CVS Health Corp.
54	CVS Pharmacy, Inc.
55	Dallas County Medical Center Delta Memorial Hospital
56	Douglas County Hospital d/b/a Alomere Health

<u>Entities from Timely Letters Requesting Exclusion</u>	
57	Drew Memorial Hospital, Inc., d/b/a/ Drew Memorial Health System Duval's Pharmacy, Inc.
58	East Boston Neighborhood Health Center Corporation Ely-Bloomenson Community Hospital
59	Eckerd
60	Erie Family Health Center, Inc.
61	ESI Mail Pharmacy Service, Inc.
62	Essentia Health, including: Brainerd Medical Center, Inc., Bridges Medical Center, Inc., Deer River Healthcare Center, Inc., Essentia Health Surgery Centers-Duluth, LLC, Essentia Health Surgery Centers-Duluth, LLC, Essentia Health Surgery Centers-North Dakota, LLC, FirstCare Medical Services, Graceville Health, Center, Innovis Health, LLC, Essentia Health-Moose Lake, Northern Pines Medical Center, Pine Medical Center, St. Joseph's Medical Center, St. Mary's Duluth Clinic Medical Center, St. Mary's Hospital of Superior, St. Mary's Innovis Health, St. Mary's Medical Center, St. Mary's Regional Health Center, and The Duluth Clinic, LTD
63	Evangelical Community Health
64	Express Scripts Holding Company
65	Express Scripts Pharmaceutical Procurement LLC
66	Express Scripts Pharmacy, Inc.
67	Express Scripts, Inc.
68	Fairview Health Services, including Fairview Pharmacy Services, LLC
69	Fresco Y Mas
70	Fulton County Medical Center
71	Gillette Children's Specialty Healthcare Glacial Ridge Health System
72	Glencoe Regional Health Services, d/b/a/ Glencoe Regional Health Granby Pharmacy, Inc., d/b/a Center Pharmacy
73	Great Lakes Bay Health Centers Great Salt Plains Health Center, Inc.
74	Greater Lawrence Family Health Center Health Partners of Western Ohio HealthPoint
75	Harveys
76	HealthSpring Life & Health Insurance Company, Inc.
77	HealthSpring of Florida, Inc.
78	HealthSpring Pharmacy of Tennessee, LLC
79	HealthSpring Pharmacy Services, LLC
80	Hennepin Healthcare System, Inc.
81	Humana Inc.
82	Humana Pharmacy, Inc. n/k/a CenterWell Pharmacy, Inc.
83	Independence Health, including Butler Health System, Butler Healthcare Providers, d/b/a Butler Memorial Hospital and d/b/a BHS Retail Pharmacy, Clarion Hospital, and Excelsa Health
84	Intermountain Health Care, Inc., including IHC Health Services, Inc. and Sisters of Charity of Leavenworth Health System, Inc.

<u>Entities from Timely Letters Requesting Exclusion</u>	
85	International Community Health Services
86	J.H. Harvey Co., LLC
87	Jackson-Madison County General Hospital District, d/b/a/ West Tennessee Healthcare
88	Knight Health Holdings LLC, d/b/a ScionHealth, including Kindred Healthcare Operating, LLC Kootenai Hospital District, an Idaho Public District Hospital, d/b/a Kootenai Health
89	Lake Region Healthcare Corporation, including Prairie Ridge Hospital & Health Services Lakewood Health System
90	Lehigh Valley Health Network, Inc., including Lehigh Valley Hospital, Inc., Pocono Medical Center, Lehigh Valley Physician Group, Lehigh Valley Health Services Inc., Northeastern Pennsylvania Health Corporation, Hazleton Professional Services, Schuylkill Health System Medical Group, Inc., Lehigh Valley Hospital – Schuylkill, Lehigh Valley Health Network Emergency Medical Services, LVHN Ambulatory Surgery Center of Lopatcong, Inc., LVHN Coordinated Professional Practice of NJ, PC, CH Eye Specialists, PC, CH Urology Specialists, PC
91	LifeCare Medical Center
92	Lifepoint Corporate Services, General Partnership
93	Lifespan Corporation, Lifespan Pharmacy, LLC, Rhode Island Hospital, The Miriam Hospital, Emma Pendleton Bradley Hospital, and Newport Hospital
94	Logan Health, including Kalispell Regional Medical Center, Inc., d/b/a Logan Health Medical Center, Logan Health - Whitefish, Logan Health - Shelby, Logan Health - Conrad, Liberty County Hospital and Nursing Home, Inc., d/b/a Logan Health - Chester, and Northern Rockies Medical Center, Inc., d/b/a Logan Health – Cut Bank
95	Longview Wellness Center, Inc. d/b/a Wellness Pointe
96	Lutheran Charity Association, d/b/a Jamestown Regional Medical Center Madelia Health
97	Lynnfield Compounding Center, Inc.
98	Lynnfield Drug, Inc.
99	Madison Health, f/k/a Madison Memorial Hospital Madison Healthcare Services, d/b/a/ Madison Hospital
100	Main Line Health, Inc., including Main Line Hospitals, Inc., and Riddle Hospital Marana Health Center, Inc.
101	Mary Rutan Hospital d/b/a Mary Rutan Health Mass General Brigham Incorporated
102	Mayo Clinic, including the Mayo Foundation for Medical Education and Research and the Mayo Medical Plan
103	Medco
104	Medco Containment Insurance Company of NY
105	Medco Containment Life Insurance Company
106	MedCura Health, Inc.
107	Medical Center, Inc.

<u>Entities from Timely Letters Requesting Exclusion</u>	
108	Memorial Hospital of Laramie County, d/b/a Cheyenne Regional Medical Center, including Cheyenne Regional Physician's Group, LLC, d/b/a Cheyenne Regional Medical Group
109	Memorial Hospital of Sweetwater County
110	Memorial Sloan Kettering Cancer Center, including Memorial Hospital for Cancer and Allied Diseases
111	Middlesex Health System, Inc., d/b/a Middlesex Health, including: Middlesex Hospital, MHS Primary Care, Inc., and Middlesex Health Services, Inc.
112	Millcreek Community Hospital Mille Lacs Health System
113	Montefiore Medical Center, including White Plains Hospital Medical Center, St. Luke's Cornwall Hospital, Montefiore New Rochelle Hospital, Montefiore Mt. Vernon Hospital, The Winifred Masterson Burke Rehabilitation Hospital, and Montefiore NYACK Hospital
114	Mount Nittany Health System, including Mount Nittany Medical Center and Mount Nittany Medical Center Health Services, Inc., d/b/a Mount Nittany Physician
115	Mount Sinai Hospitals Group, Inc., including The Mount Sinai Medical Center, Inc., The Mount Sinai Hospital, South Nassau Communities Hospital, Beth Israel Medical Center, The St. Luke's-Roosevelt Hospital Center, The New York Eye and Ear Infirmary, and Icahn School of Medicine at Mount Sinai
116	Murray County Medical Center MVMEDSHOP, Inc., d/b/a/ Vineyard Scripts
117	Nationwide Children's Hospital, including Nationwide Children's Hospital Homecare North Big Horn Hospital District
118	North Canyon Medical Center, Inc., including Partners on Healthcare, Inc. d/b/a North Canyon Medical Center
119	North Memorial Health Care, d/b/a North Memorial Health, including Maple Grove Hospital Corporation, d/b/a Maple Grove Hospital
120	North Olympic Healthcare Network
121	Northern Itasca Hospital District, d/b/a Bigfork Valley Northfield Hospitals + Clinics, Inc.
122	Novant Health, Inc.
123	Nuvance Health, including Eastern New York Medical Services, P.C., Health Quest Home Care, Inc., Health Quest Systems, Inc., Hudson Valley Cardiovascular Practice, P.C., Northern Dutchess Hospital, Nuvance Health Medical Practice CT, Inc., Nuvance Health Medical Practice, P.C., Putnam Hospital Center, d/b/a Putnam Hospital, S.W.C. Corporation, The Danbury Hospital, d/b/a Danbury Hospital, The Norwalk Hospital Association, d/b/a Norwalk Hospital, Vassar Health Connecticut, Inc., d/b/a Sharon Hospital, Vassar Brothers Hospital, d/b/a Vassar Brothers Medical Center, Western Connecticut Health Network Affiliates, Inc., and Western Connecticut Home Care, Inc.
124	NYU Langone Hospitals
125	Ochsner Clinic Foundation, including Ochsner Outpatient and Home Infusion Pharmacy, L.L.C. and Ochsner Pharmacy & Wellness, L.L.C.
126	Olmsted Medical Center Ortonville Area Health Services Overlake Hospital Medical Center
127	Omnicare

<u>Entities from Timely Letters Requesting Exclusion</u>	
128	Optum Rx Group Holdings, Inc.
129	Optum Rx, Inc.
130	OptumRx Holdings, LLC
131	PeaceHealth
132	Peak Vista Community Health Centers
133	Penn Highlands Healthcare, including: DuBois Regional Medical Center, d/b/a Penn Highlands Dubois, Brookville Hospital, d/b/a Penn Highlands Brookville, DuBois Regional Medical Center, d/b/a Penn Highlands Clearfield, Elk Regional Medical Center, d/b/a Penn Highlands Elk, J.C. Blair Memorial Hospital, d/b/a Penn Highlands Huntingdon, Tyrone Hospital, d/b/a Penn Highlands Tyrone, Highlands Hospital, d/b/a Penn Highlands Connellsville, and Monongahela Valley, d/b/a Penn Highlands Mon Valley
134	Perham Hospital District, d/b/a/ Perham Health Pikeville Medical Center
135	Priority Healthcare Corporation
136	Priority Healthcare Distribution, Inc.
137	Providence St. Joseph Health, including Providence Health & Services – Washington, Providence Health & Services – Western, Washington Providence Health System – Southern California, Mission Hospital Regional Medical Center, Mission Hospital Laguna Beach, Providence Saint John's Health Center, Providence TrinityCare Hospice, St Joseph Hospital of Orange, St Mary Medical Center Providence, St Joseph Medical Center (Montana), Providence Health & Services – Montana Credena Health, LLC, Providence Health & Services – Oregon, Kadlec Regional Medical Center, Pacmed Clinics, Providence Medical Institute, Providence Medical Foundation, Providence Facey Medical Foundation, Providence Saint John's Medical Foundation, St. Joseph Health Northern California, LLC, NorCal HealthConnect, LLC, Methodist Children's Hospital, Methodist Hospital Levelland, Methodist Hospital, Plainview, Texas, Covenant Medical Center Covenant Long-Term Care, LLC, Covenant Medical Group, Covenant High Plains Surgery Center, LLC, Lubbock Heritage Hospital, LLC, Swedish Health Services, Swedish Edmonds, Mission Ambulatory Surgicenter, Ltd., St. Joseph Health System Home Care Services, LLC, Tarzana Medical Center, LLC, St Jude Hospital, Express Care LLC, Clackamas Radiology Oncology Center, LLC, CSS JV, LLC
138	Pueblo Community Health Center, Inc.
139	RAD Sub-Trust A
140	Ridgeview Medical Center, Inc., d/b/a Ridgeview, including Sibley Medical Center, d/b/a Ridgeview Sibley Medical Center
141	Rite Aid Corporation
142	Rite Aid Hdqtrs. Corp.
143	River's Edge Hospital
144	Riverview Healthcare Association
145	Roanoke Chowan Community Health Center
146	Rutherford County Primary Care Clinics, Inc., d/b/a Primary Care & Hope Clinic

<u>Entities from Timely Letters Requesting Exclusion</u>	
147	RWJBarnabas Health, Inc., including Livingston Infusion Care, Inc., d/b/a Qualitas Pharmacy Services, LSC Pharmacy Services, Inc., d/b/a Barnabas Health Retail Pharmacy, Barnabas Health, Inc., and RWJBH Corporate Services, Inc. (f/k/a Barnabas Health, Inc.)
148	Salem Community Hospital, d/b/a Salem Regional Medical Center Sanford, including Sanford West, Sanford North, Sanford West Select Medical Corporation
149	Sam's Club
150	Samson Merger Sub, LLC
151	Save-Rite
152	SGOH Acquisition, Inc., d/b/a/ Ozarks Community Hospital
153	Shands Teaching Hospital and Clinics, Inc., and Shands Jacksonville Medical Center, Inc., including Central Florida Health, Inc., d/b/a UF Health Central Florida, Leesburg Regional Medical Center, Inc., d/b/a UF Health Leesburg Hospital, and The Villages Tri- County Medical Center, Inc., d/b/a UF Health The Villages Hospital. Shands Teaching Hospital and Clinics, Inc. and Shands Jacksonville Medical Center, Inc., and all assigning subsidiaries and affiliates thereof
154	Shasta Community Health Center
155	Shawnee Health Service and Development Corporation Sleepy Eye Medical Center
156	Shopko Stores Operating Co. LLC
157	Southeastern Grocers, Inc.
158	Southeastern Grocers, LLC
159	Specialty Products Acquisitions, LLC
160	Specialty Retail Shops Holding Corp.
161	St. Clair Health Corp., d/b/a St. Clair Health, including its affiliates St. Clair Memorial Hospital, d/b/a St. Clair Hospital and St. Clair Medical Services, d/b/a St. Clair Medical Group
162	St. Luke's Health Network, Inc., d/b/a St. Luke's University Health Network, including: GSL Hospital, d/b/a Geisinger St. Luke's Hospital, Saint Luke's Hospital of Bethlehem, Pennsylvania, and St. Luke's Homestar Services, LLC, d/b/a St. Luke's Homestar Pharmacy
163	St. Luke's Health System, Ltd., including St. Luke's Magic Valley Regional Medical Center, Ltd., St. Luke's Wood River Medical Center, Ltd., St. Luke's Regional Medical Center, Ltd., St. Luke's McCall, Ltd., and St. Luke's Nampa Medical Center, Ltd.
164	St. Luke's Hospital of Duluth, including Lake View Memorial Hospital, Inc. St. Thomas Community Health Center
165	Stamford Health, Inc., including Stamford Health Pharmacy LLC Stigler Health & Wellness Center, Inc.
166	Superbrand
167	Sweet Bay
168	Syringa Hospital Districts, d/b/a/ Syringa Hospital & Clinics
169	Taurus Acquisition Group LLC
170	Tel-Drug of Pennsylvania, LLC

<u>Entities from Timely Letters Requesting Exclusion</u>	
171	Tel-Drug, Inc.
172	The Chautauqua Center, Inc.
173	The Children's Hospital Corporation, d/b/a Boston Children's Hospital The Children's Hospital of Philadelphia
174	The Cigna Group
175	The DCH Health Care Authority, d/b/a DCH Health System The Guthrie Clinic
176	The New York and Presbyterian Hospital
177	The Regents of the University of Michigan on behalf of University of Michigan Health, including Metropolitan Hospital
178	Thomas Jefferson University, d/b/a/ Jefferson Health, including Abington Health, Abington Health Foundation, Lansdale Hospital, Abington Memorial Hospital, Jefferson Health – Northeast System, Aria Health Physician Services, Jefferson Health – Northeast, Aria Health Orthopedics, Medical Imaging Associates, LLC, Jefferson Health – Northeast Foundation, TMB, Enterprises, System Service Corporation, T.F. Development Ltd., Juniata Medical Building Partners, Health Care, Inc., Aria Health Orthopedics of New Jersey, P.C., Kennedy Health System, Inc., Jefferson Health New Jersey Direct Primary Care, P.C., Kennedy Access Incorporated, Kennedy Health Care Foundation, Inc., Kennedy Health Facilities, Inc., Kennedy Management Group, Inc., Kennedy Medical Group Practice, P.C., Kennedy Property Corp., Kennedy University Hospital, Inc., Stat Medical Transport, Inc., The Magee Memorial Hospital for Convalescents, TJUH System, Jefferson Physician Services, Jefferson Medical Care, Jefferson University Physicians, Jefferson University Physicians of New Jersey, P.C., Thomas Jefferson University Hospitals, Inc., Jefferson Acute Care Physicians, LLC, Jefferson Ambulatory Surgery Services, LLC, Jefferson Ambulatory Surgery Real Estate Holdings, LLC, Jeffex, Inc., Emergency Transport Associates, Inc., Suthbreit Properties, Ltd., Walnut Home Therapeutics, Inc., Methodist Associates in Healthcare, Inc., Methodist Associates in Healthcare of New Jersey, P.C., Mid-Atlantic Maternal Fetal Institute, Inc., The Atrium Corporation, Health Services, LLC, Healthmark Incorporated, Albert Einstein Healthcare Network, Einstein Practice Plan, Inc., Einstein Community Health Associates, Inc., Fornance Physician Services, Albert Einstein Medical Center, GHMC Management, Inc., Rehab Ventures, Inc., Einstein Medical Center Montgomery, Montgomery Hospital, Montgomery Health Foundation, CMMC, Inc., Einstein Healthcare Systems, Inc., BCCT Over Corp., Einstein Care Partners, LLC, Network Physicians of New Jersey, TJ-Non Qualified, LLC, TJ-Qualified, LLC, T.J.U., Inc., 1100 Walnut Associates, LLP, JeffPM, LLC, The Jefferson Club, JeffHedge, LLC, Walnut Realty Co., TJU Fairwater, LLC, 925 Walnut Holding, LLC, 925 Walnut Corp., Bildex Corp., Jefferson Horizon Research, LLC, Philadelphia University, JeffCare, Inc., JeffCare Alliance, LLC
179	Tri-Area Community Health
180	UC Health, LLC, d/b/a UC Health UHS of Delaware, Inc.
181	UMass Memorial Care, Inc. United Hospital District
182	United HealthCare Services, Inc. and its subsidiaries and affiliates

<u>Entities from Timely Letters Requesting Exclusion</u>	
183	University Health Systems of Eastern Carolina, d/b/a ECU Health, including Duplin General Hospital, Inc., d/b/a ECU Health Duplin Hospital, East Carolina Health-Bertie, d/b/a ECU Health Bertie Hospital, East Carolina Health-Chowan, Inc., d/b/a ECU Health Chowan Hospital, East Carolina Health-Heritage, Inc., d/b/a ECU Health Edgecombe Hospital, Halifax Regional Medical Center, Inc., d/b/a ECU Health North Hospital, East Carolina Health, d/b/a ECU Health Roanoke Chowan Hospital, Pitt County Memorial Hospital, Incorporated, d/b/a ECU Health Medical Center, and The Outer Banks Hospital, Inc.
184	Upham's Corner Health Committee, Inc., d/b/a Upham's Corner Health Center
185	UPMC, including UPMC Presbyterian Shadyside, UPMC Sunbury, UPMC Children's Hospital of Pittsburgh, UPMC Wellsboro, UPMC Magee-Women's Hospital, UPMC Chautauqua Services, Inc., UPMC St. Margaret, UPMC Chautauqua at WCA, UPMC Passavant, UPMC Carlisle, UPMC McKeesport, UPMC Pinnacle, UPMC Mercy, UPMC Lititz, UPMC Bedford, UPMC Memorial, UPMC Lee, Pinnacle Health Regional Physicians, UPMC East, Pinnacle Health Cardiovascular Institute, Inc., UPMC Hamot, UPMC Hanover, UPMC Horizon, UPMC Pinnacle Hospitals, UPMC Northwest, Western Maryland Physician Network, UPMC Altoona, University of Pittsburgh Cancer Institute Cancer Services, UPMC Jameson, Hematology Oncology Association, Charles Cole Memorial Hospital, Oncology-Hematology Association, Inc., UPMC Susquehanna, Renaissance Family Practice - UPMC, Inc., UPMC Pinnacle, Tri-State Neurosurgical Associates - UPMC, Inc., UPMC Somerset, UPMC Home Health Care of Western Pennsylvania, University of Pittsburgh Physicians, UPMC Home Health Care of Central Pennsylvania, UPMC Western Maryland, Sugarcreek Station, UPMC Kane, Cranberry Place, Regional Health Services, The Heritage Place, Great Lakes Physician Practice, Inc., Seneca Place, UPMC Altoona Regional Health Services, Jameson Care Center, Inc., Jameson Medical Care, Inc., South Central Alpha Housing and Healthcare, Inc., UPMC Muncy, South Western Alpha Housing and Healthcare, Inc., Divine Providence Hospital of the Sisters of Christian Charity, Canterbury Place, Susquehanna Physician Services Asbury Heights of UPMC, UPMC Williamsport, Asbury Health Center, UPMC Lock Haven, Asbury Place
186	Valley Health Network, Inc.
187	Valor Health
188	WakeMed, d/b/a WakeMed Health & Hospitals Welia Health
189	Walmart Inc.
190	Wellpath LLC, including Correctional Medical Group Companies White River Health System, Inc., d/b/a/ White River Medical Center Winona Health Services
191	Winn-Dixie Corporation
192	Winn-Dixie Logistics, Inc.
193	Winn-Dixie Procurement, Inc.
194	Winn-Dixie Stores, Inc.

EXHIBIT F

<u>Clobetasol Class Members from Timely Letters Requesting Exclusion</u>	
1	CATAMARAN
2	CIGNA
3	CVS CAREMARK
4	EXPRESS SCRIPTS
5	HUMANA
6	OMNICARE
7	OPTUM RX
8	PRIME THERAPEUTICS
9	PRIORITY HEALTHCARE
10	WALMART
11	WINN DIXIE

<u>Clomipramine Class Members from Timely Letters Requesting Exclusion</u>	
1	CIGNA
2	EXPRESS SCRIPTS
3	HUMANA
4	MEDCO
5	OMNICARE
6	OPTUM RX
7	RITE AID
8	WALMART
9	WINN DIXIE

EXHIBIT G

<u>Entities from Untimely Letter Requesting Exclusion</u>	
1	Acme Markets
2	Albertson's, Inc.
3	Albertsons
4	Albertsons Companies LLC
5	Albertsons Companies, Inc.
6	Albertsons LLC
7	Albertsons Market
8	Alliance
9	Alliance BMP
10	Alliance Boots
11	Alliance Healthcare
12	Alliance Rx Walgreens Prime Pharmacy
13	Alliance Santé
14	Alliance UniChem
15	American Drug Stores
16	American Stores Company
17	Andronico's
18	Andronico's Community Markets
19	Baker's
20	Balducci's Food Lover's Markets
21	Bowen Development
22	Burlington Drug
23	Burlington Drug Company
24	Burrells
25	Burrells Limited
26	Carr-Gottstein Foods Co.
27	City Market
28	Company Amigos United
29	Copps Food Center
30	Cystic Fibrosis Services
31	Cystic Fibrosis Services Inc.
32	Cystic Fibrosis Services LLC
33	Dillon
34	Dillon Companies, Inc.
35	Dominick's
36	Dominick's Finer Foods, LLC
37	Duane Reade
38	Duane Reade, Inc.

<u>Entities from Untimely Letter Requesting Exclusion</u>	
39	Extreme Value
40	Extreme Value Centers
41	FMJ, Inc.
42	Food 4 Less
43	Food 4 Less Holdings, Inc.
44	Foods Pavilion
45	Fred Meyer
46	Fred Meyer Jewelers, Inc.
47	Fred Meyer Stores, Inc.
48	Fred Meyer, Inc.
49	Fry's
50	Genuardi's
51	Genuardi's Family Markets LP
52	Gerbes
53	Globe Stores
54	Green Hills Insurance
55	Haggen
56	Haggen Food & Pharmacy
57	Happy Harry's Inc.
58	Happy Harry's
59	Happy Harry's Discount Drug Stores, Inc.
60	Harris Teeter
61	Harris Teeter, Inc.
62	Harris Teeter, LLC
63	Healthy Options, Inc.
64	Home Chef
65	Infinity Infusion
66	J M Smith
67	J M Smith Corporation
68	Jay C Food Stores
69	Jerseymaid Milk Products
70	Jewel Food Stores
71	Jewel Foods
72	Jewel Foods, Inc.
73	Jewel-Osco Pharmacy
74	Junior Food Stores of West Florida, Inc.
75	Kerr Drug
76	Kessel

<u>Entities from Untimely Letter Requesting Exclusion</u>	
77	Kessel Food Markets, Inc.
78	King Soopers
79	Kings Food Markets
80	Kiosk Medicine Kentucky, LLC
81	KRGP Inc.
82	Kroger
83	Kroger Limited Partnership I
84	Kroger Limited Partnership II
85	Kroger Texas L.P.
86	Lawrence Brothers
87	Lawrence Brothers Co.
88	Lawrence Brothers Pharmacy
89	Lucerne Foods, Inc.
90	Lucky Stores (Utah locations)
91	Mariano's Fresh Market
92	Market Street
93	Matthews Property 1, LLC
94	May's Drug Stores
95	May's Drug Stores, Inc.
96	Medicenter
97	Med-X
98	Med-X Corporation
99	Metro Market
100	New Albertson's Inc.
101	New Albertsons L.P.
102	Oscos Drugs
103	Owen's
104	Owen's Supermarket
105	Pak 'N Sav
106	Paul's Market
107	Pavilions Place Randall's
108	Pay Less Super Markets
109	Peyton's
110	Peyton's Pheonix
111	Peyton's Fountain
112	Peyton's Mid-South Company
113	Peyton's Northern
114	Peyton's-Southeastern, Inc.
115	Pick 'n Save

<u>Entities from Untimely Letter Requesting Exclusion</u>	
116	Postal Prescription Services
117	Prime Therapeutics Specialty Pharmacy
118	Prime Therapeutics Specialty Pharmacy LLC
119	QFC
120	Raley's of New Mexico
121	Ralphs
122	Ralphs Grocery Company
123	Randall's Food & Drugs LP
124	Riviera Brands
125	Roundy's Inc.
126	Ruler Foods
127	S & W Pharmacy, Inc.
128	S&W Pharmacy
129	Safeway
130	Safeway Food & Drug
131	Safeway Inc.
132	Sav-On Drug
133	Scott's Foods
134	Scott's Pharmacy
135	Shaw's Supermarkets, Inc.
136	Shop-Rite, LLC
137	Simon David
138	Smith Drug
139	Smith Drug Company
140	Smith's
141	Smith's Food & Drug Centers, Inc.
142	Star Market
143	Sunrise R&D Holdings, LLC
144	Sunrise Technology LLC
145	Super D. Drugs Acquisition Co.
146	Super Saver Foods
147	Superior
148	Superior Acquisitions Limited
149	Superior Holdings Limited
150	The Kroger Co.
151	The Kroger Co. of Michigan
152	The Vons Companies, Inc.
153	TLC Corporate Services LLC
154	Tom Thumb Food & Drugs

<u>Entities from Untimely Letter Requesting Exclusion</u>	
155	Trinity Home Care
156	United Express
157	United Supermarkets
158	United Supermarkets, LLC
159	USA Drug
160	USA/Super D Franchising
161	Vons
162	Vons Grocery Company
163	Walgreen
164	Walgreen Co.
165	Walgreen Company
166	Walgreens

EXHIBIT H

<u>Clobetasol Class Members from Untimely Letter Requesting Exclusion</u>	
1	ALBERTSONS
2	BURLINGTON DRUG
3	HE BUTT
4	J M SMITH CORP
5	KROGER COMPANY
6	PEYTONS
7	SAFEWAY
8	SMITH DRUG

<u>Clomipramine Class Members from Untimely Letter Requesting Exclusion</u>	
1	ALBERTSONS
2	BURLINGTON DRUG
3	HE BUTT
4	J M SMITH CORP
5	KERR DRUG
6	KROGER COMPANY
7	SMITH DRUG